Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Sector movers: Astra, Glaxo drag down pharmas

Tue, 20th Dec 2011 12:52

The pharmaceuticals were on the decline today, dragged lower by sector giant AstraZeneca.AstraZeneca warned this morning that earnings will come in at the lower end of expectations after it took a $381.5m hit from failed drug tests. The company has stopped development of its ovarian cancer treatment olaparib and also said its antidepressant compound TC-5214 had not met targets. As a result, AstraZeneca will take pre-tax impairment charges totalling $381.5m to R&D expense in the fourth quarter of 2011, it said. These impairments would push down the company's core earnings per share by around $0.21 in the fourth quarter, it said. This meant that while full year core EPS would remain in the predicted range of $7.20 to $7.40, earnings were likely to be in the lower half of this scale.Sector peer GlaxoSmithKline joined Astra in the red despite announcing that it is to return £242m to shareholders next year after the sale of its non-core Consumer Healthcare OTC brands in the US and Canada for £426m."The disposal of our non-core consumer brands is about realising attractive value for shareholders as well as simplifying our ongoing Consumer business and allowing it to focus on its priority brands and markets," said Chief Financial Officer Simon Dingemans. Heading the other way were media stocks with one of the biggest of them all, advertising giant WPP, providing a lift.Shares in Sir Martin Sorrell's firm were boosted higher today after it announced that it had acquired a 49% stake in Chinese peer Nanjing Yindu Advertising and Commerco Co for an undisclosed sum.The acquisition was made through WPP's advertising and marketing business Ogilvy & Mather and expands this unit's reach into the "crucial" region of Yangtza River Delta. "In strengthening Ogilvy's offering, as it does, in second-tier cities this initiative underlines WPP's regional approach in China, not confined to the coastal region," the statement said. Sector peers ITV, UBM and BSkyB were also lifting the sector higher today.BCTop performing sectors so far todayAutomobiles & Parts 4,044.85 +1.64%Construction & Materials 3,211.55 +1.29%Media 3,849.27 +1.15%Life Insurance 3,673.71 +0.98%Industrial Engineering 6,794.32 +0.77%Bottom performing sectors so far todayPharmaceuticals & Biotechnology 9,741.72 -1.85%Tobacco 33,999.55 -0.83%Electronic & Electrical Equipment 2,530.28 -0.70%Equity Investment Instruments 5,208.74 -0.63%Beverages 9,922.19 -0.59%

Related Shares

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslode...

18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.